創益生技股份有限公司
Navigation
Toggle navigation
SELECT YOUR LANGUAGE
繁體中文
English
简体中文
回首页
繁體中文
English
简体中文
繁體中文
简体中文
English
About us
Introduction
Milestones
Management Team
Board of Directors
Corporate
Management corporate structure
Shareholder Resolutions
Rules and Regulations
Corporate Responsibility
International Partners
News
Latest Information
Products
Reducing Allergy Symptoms
Orthopedic Health
Metabolism
OEM/ODM
Anti-Allergy Website
contact
R&D Achievement
Body Conditioning
Gastrointestinal Health Care
Investors
events & news
News and Announcement
Corporate Information
Investor Meeting
Rules and Regulation
Management corporate structure
Shareholder Resolutions
Rules and Regulations
Financial Report
Financial Report
Monthly Revenue
Corporate Annual Report
Contact
Investor Area
Corporate Relation Area
Contact Us
Contact Information
Contact Form
Corporate
Corporate Benefits
Corporate Culture
Training and Development
Join Chuang Yi
About us
News
Products
Investors
Contact Us
繁
En
简
Banner Up
News
News
HOME
News
Latest Information
MENU
Latest Information
Latest Information
沛麗婷®® BELVIQ® Authentic Packaging Identification Method
2018/04/10
If you find any unidentified counterfeit drugs, please report it to the Department of Health and Welfare immediately. The report line: 0800-285-0001.
1. Belviq leaflet is approved by the Ministry of Health and Welfare which contained the Chinese product name and license number 027218.
2. The outer box is affixed with anti-counterfeit laser label and scratch coating QR code.
Chuang Yi Biotech (CYB) (6566) announces Taiwan Food and Drug Administration (TFDA) has officially approved BELVIQ® (沛麗婷), a new weight-loss drug with new ingredients.
2017/07/31
Chuang Yi Biotech (CYB) (6566) today announced that Taiwan Food and Drug Administration (TFDA) approved BELVIQ® (沛麗婷), MHW Import No. 027218, and would be launched in Q4 2017 in Taiwan.
More
Footer
